Business Wire

SCIOTEQ

15.2.2024 12:01:28 CET | Business Wire | Press release

Share
ScioTeq Expands Operations into Bangalore, India for Advanced Visualization & Computing Displays

ScioTeq, a leading provider of mission-critical defense and avionics visualization and computing solutions, announces the establishment in Bangalore, India of ScioTeq Pvt Ltd, a wholly owned subsidiary of ScioTeq bv. This move will further extend ScioTeq’s global presence by providing Sales, Procurement and Services at its Bangalore location. Additionally, by joining with local partners it will position ScioTeq to support local trade sales and manufacturing of its products and solutions for the Defense market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215830655/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ScioTeq Group Worldwide Locations. (Photo: Business Wire)

This move aligns with the “Make in India” initiative of the Government of India to create and encourage companies to develop, manufacture and assemble products made in India and incentivize dedicated investments into manufacturing. The policy creates a conducive environment for business investment, while building a modern structure and opening new sectors for capital investment. It also creates additional jobs that align with the government’s mantra “Atmanirbhar Bharat” (Self Reliant India) which is focused on promoting indigenization in the Defense sector.

“ScioTeq is excited to evolve our long-term relationship with India’s defense community to the next level with this newly established subsidiary,” said ScioTeq Vice President of Defense & Security, Klaas Peerlinck. “It confirms our commitment as a partner in India’s defense manufacturing establishment as well as providing a base to provide dedicated service and sales needs.”

India’s Defense budget is the fourth largest in the world thus providing various opportunities for Defense industries to engage and partner with them as they develop and upgrade their military capabilities. ScioTeq, the largest independent advanced visualization company globally, has engaged with the Indian defense establishment for over two decades, providing critical visualization solutions. This long-term experience in the country, robust portfolio of visualization and computing displays and now a local base of operations, amply positions ScioTeq for future growth and provides the Indian Defense sector with visualization and computing solutions across all three of its services - the Navy, Army, and Air Force.

“We welcome the move by ScioTeq in incorporating a wholly owned subsidiary in India to drive indigenous manufacturing of their products. We value our association and look forward to working with them,” said Mr. Arun Ramchandani, Head of Larsen & Toubro Defence (L&T). L&T is a multinational Indian conglomerate engaged in various industry sectors including defense.

About ScioTeq

ScioTeq has 35+ years’ experience designing, engineering and manufacturing high-tech, innovative, life- and mission-critical computing & visualization solutions for the Air Traffic Control, Avionics and Defense & Security markets. With headquarters in Belgium and five additional locations worldwide, they are a trusted partner in advanced computing & visualization solutions. ScioTeq products are used in the air, on the ground and at sea, delivering mission-critical information to operators on some of the most advanced platforms on the planet and in some of the most challenging environments.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215830655/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye